Clinical Data And GuidanceStrong physician feedback and supportive Phase II results for Nemluvio in chronic itch increase the likelihood that management will raise peak sales guidance above current consensus.
Product LaunchesLaunches of Nemluvio and Relfydess, together with introduction of differentiated fillers into the US market, are positioned to expand market share and accelerate sales momentum.
Strategic InvestmentL'Oreal's planned increase to a 20% stake and potential nomination of two board members should deepen scientific collaboration and broaden access to marketing resources, supporting long-term revenue expansion.